Protalix Israeli oo Germany’s Secarna kala shaqaynaysa daawaynta cudurka kelyaha ee naadirka ah
Israa'iil: Protalix BioTherapeutics oo la shuraakoobtay Secarna Pharmaceuticals si loo horumariyo daawaynta cudurrada kelyaha ee naadirka ah, iyadoo la adeegsanayo AI.
Yeruusaalem, 18 December, 2025 (TPS-IL) — Shirkadda dawooyinka ee Israa’iil ee Protalix BioTherapeutics ayaa heshiis iskaashi iyo doorasho la saxiixatay shirkadda Secarna Pharmaceuticals ee dalka Jarmalka, si ay si wadajir ah u horumariyaan dawooyinka antisense oligonucleotide ee cudurrada dhifta ah ee kelyaha. Sida ku cad heshiiska, Protalix ayaa dooran doonta bartilmaameedyada bayoolojiga, halka Secarna ay isticmaali doonto madal ay ku shaqeyso AI oo la yiraahdo OligoCreator si ay u naqshadayso oo ay u qiimayso musharraxiinta dawooyinka. Wada-shaqaynta ayaa doonaysa inay horumariso barnaamijyada la doortay laga bilaabo cilmi-baarista horudhaca ah ilaa tijaabooyinka caafimaad.
Protalix waxa ay heshay doorasho ay ku yeelato ruqsad gaar ah oo caalami ah si ay u sii horumariso, u ganacsiayso, una suuq-geleyso dawooyinka ka soo bixi doona, iyadoo la siinayo Secarna lacago horumarineed iyo kuwo boqolkiiba ah. Heshiiskan waxa uu calaamadinayaa ballaarinta Protalix ee dawooyinka ku salaysan RNA ee xaaladaha dhifta ah ee kelyaha.
